Deep-pocketed investors have adopted a bullish approach towards Walt Disney (NYSE:DIS), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DIS usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Walt Disn ...

Oil, LNG Shares Soar on Middle East Conflict**FROM 4 hr 6 min agoStock futures may be sinking Monday morning because of the escalating conflict in the Middle East, but it is proving beneficial to energy shares.Big oil stocks and those of [liquefied natural gas (LNG)] (https://www.investopedia.com/terms/l/liquefied-natural-gas.asp) providers are soaring before the bell along with [West Texas Intermediate] (https://www.investopedia.com/terms/w/wti.asp) crude and natural gas futures, which jumped about 8% and ...

Key Takeaways CCBG raised its quarterly dividend 3.8% to 27 cents per share, marking its eighth hike in five years.RRBI boosted its payout 67% to 25 cents, with 2026 sales and earnings seen rising year over year.SFNC increased its dividend 1.2% to 21.5 cents. It offers a 4.27% yield with a 50% payout ratio.The year 2026 began on a subdued note. The S&P 500 increased modestly and the Dow Jones Industrial Average gained 1.9%, while the Nasdaq declined roughly 2.5%. The markets were weighed down by AI-related ...

Key Takeaways PFE shares have gained 11% YTD, trading above 50- and 200-day SMAs since early January.Pfizer's oncology and new products drove 2025 growth, with non-COVID revenues up 6%.PFE guides 2026 revenues of $59.5B-$62.5B and EPS of $2.80-$3.00, hurt by COVID decline and patent losses.Pfizer’s (PFE) stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January.Image Source: Zacks Investment ResearchPfizer ...

Key Takeaways Middle East tensions raise oil supply risks, supporting bullish energy trades.Modest OPEC output hike may fail to offset geopolitical supply concerns.Leveraged oil ETFs may offer short-term upside but carry elevated volatility risks.The United States and Israel launched coordinated strikes on Iran on Feb. 28, 2026, with President Donald Trump saying the operation aimed to destroy Iran’s nuclear program and weaken the current regime.The attacks prompted immediate retaliation from Iran and raise ...

Company Overview - Wix.com is a leading provider of cloud-based web development solutions, enabling users to build, manage, and grow their digital presence [6] - The company operates on a subscription-based business model, supported by a suite of complementary services and payment solutions, driving recurring revenue and customer engagement [6] - Wix.com targets individuals, small businesses, and enterprises globally, offering a range of products including Wix Editor, Wix ADI, and Wix Payments [8] Financial Performance - For the trailing twelve months (TTM), Wix.com reported revenue of $1.93 billion and a net income of $138.90 million [4] - As of February 17, 2026, Wix.com had a market capitalization of $3.8 billion [4] - In the third quarter, revenue increased by 14% year over year to $505.2 million, with total bookings also rising by 14% to $514.5 million [9] Recent Developments - No Street Capital sold 50,000 shares of Wix.com, valued at approximately $6.05 million, reducing its stake in the company [2] - Following the sale, Wix.com represented 3.5% of No Street GP LP's 13F assets, placing it outside the fund's top five holdings [7] - As of the sale date, Wix shares were priced at $68.07, reflecting a 70% decline over the past year, significantly underperforming the S&P 500, which increased by about 17% [7] Future Outlook - Management anticipates approximately $600 million in free cash flow for 2025, excluding acquisition costs, with free cash flow reaching $127.3 million in the third quarter [9] - The company is transitioning into an AI-enabled platform, with expectations of at least $50 million in annual recurring revenue (ARR) from its AI application-builder by year-end [10] - The ongoing execution in AI and margin discipline will be critical in determining whether Wix.com represents a value trap or a significant reset in its business model [11]

Company Overview - Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a key player in the medical technology sector, focusing on advanced silicone breast implants [1] Financial Performance - ESTA's Return on Invested Capital (ROIC) is -12.48%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 9.01%, indicating insufficient returns to cover capital costs [2] - The negative ROIC to WACC ratio for ESTA is -1.39, highlighting the company's challenges in generating adequate returns [2] Comparative Analysis - OrthoPediatrics Corp. (KIDS) has a ROIC of -6.27% and a WACC of 8.86%, resulting in a ROIC to WACC ratio of -0.71, which is better than ESTA's performance [3] - SI-BONE, Inc. (SIBN) shows a ROIC of -10.42% and a WACC of 7.50%, leading to a similar ROIC to WACC ratio of -1.39 as ESTA [3] - Crinetics Pharmaceuticals, Inc. (CRNX) faces a severe situation with a ROIC of -49.33% and a WACC of 4.44%, resulting in a ROIC to WACC ratio of -11.10 [4] - In contrast, LivaNova PLC (LIVN) has a positive ROIC of 10.90% and a WACC of 7.96%, achieving a favorable ROIC to WACC ratio of 1.37, indicating efficient capital utilization [4]

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against PayPal Holdings, Inc. (NASDAQ: PYPL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired PayPal securities between February 25, 2025 and February 2, 2026, bo ...

Core Insights - Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on therapies for neurological and immunoscience diseases, attracting investor and analyst attention due to its innovative treatment approaches [1] - The average price target for Biohaven increased to $23 last month, reflecting a positive outlook from analysts compared to the previous quarter, with BTIG setting a target of $24, indicating a potential rally of 82.2% [2][6] - Analysts' optimism is supported by an increase in the average price target from $18.67 three months ago to $23, suggesting favorable developments in clinical trials or market conditions [3] - A year ago, the average price target was $31.5, indicating challenges over the past year, but the recent upward trend suggests potential recovery and positive developments, with Biohaven receiving a Zacks Rank 2 (Buy) [4] - Recent news, including clinical trial progress and regulatory approvals, could significantly impact analysts' expectations and price targets, with positive developments likely leading to further increases [5]

protection#9ef7f0f8f1def8ecfff0f5fdecebe4f2ffe9b0fdf1f3) Call us at: 310-914-5007Visit our website at: [www.frankcruzlaw.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4629499- 1&h=1505463290&u=https%3A%2F%2Fwww.frankcruzlaw.com%2F&a=www.frankcruzlaw.com) Follow us for updates on Twitter: [twitter.com/FRC_LAW](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4629499- 1&h=1675080152&u=https%3A%2F%2Ftwitter.com%2FFRC_LAW&a=twitter.com%2FFRC_LAW).If you inquire by email, please include your mailing address, ...